This company listing is no longer active
Sirnaomics Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Sirnaomics's earnings have been declining at an average annual rate of -2.7%, while the Biotechs industry saw earnings growing at 31.7% annually. Revenues have been growing at an average rate of 37.9% per year.
Información clave
-2.7%
Tasa de crecimiento de los beneficios
30.3%
Tasa de crecimiento del BPA
| Crecimiento de la industria Biotechs | 11.0% |
| Tasa de crecimiento de los ingresos | 37.9% |
| Rentabilidad financiera | n/a |
| Margen neto | -7,587.8% |
| Última actualización de beneficios | 30 Jun 2024 |
Actualizaciones de resultados anteriores recientes
Recent updates
Desglose de ingresos y gastos
Cómo gana y gasta dinero Sirnaomics. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 30 Jun 24 | 1 | -82 | 23 | 38 |
| 31 Mar 24 | 1 | -80 | 23 | 46 |
| 31 Dec 23 | 0 | -79 | 23 | 54 |
| 30 Sep 23 | 0 | -82 | 24 | 60 |
| 30 Jun 23 | 0 | -84 | 24 | 66 |
| 31 Mar 23 | 0 | -86 | 24 | 67 |
| 31 Dec 22 | 1 | -88 | 24 | 68 |
| 30 Sep 22 | 1 | -230 | 25 | 69 |
| 30 Jun 22 | 1 | -223 | 22 | 60 |
| 31 Mar 22 | 0 | -218 | 19 | 51 |
| 31 Dec 21 | 0 | -213 | 16 | 41 |
| 30 Sep 21 | 0 | -60 | 10 | 27 |
| 31 Dec 20 | 0 | -44 | 5 | 15 |
| 31 Dec 19 | 0 | -16 | 5 | 10 |
Ingresos de calidad: 2257 is currently unprofitable.
Margen de beneficios creciente: 2257 is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: 2257 is unprofitable, and losses have increased over the past 5 years at a rate of 2.7% per year.
Acelerando crecimiento: Unable to compare 2257's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: 2257 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (14.7%).
Rentabilidad financiera
Alta ROE: 2257's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.